Skip to main content

Table 4 Mean PK parameters of abediterol in patients with COPD

From: Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD

Parameter (unit)

Abediterol 0.625 μg

Abediterol 2.5 μg

Abediterol 5 μg

Abediterol 10 μg

(n = 19)

(n = 19)

(n = 19)

(n = 20)

mean

(SD)

mean

(SD)

mean

(SD)

mean

(SD)

Cmax (pg/mL)

0.374

0.195

1.230

0.637

2.24

0.927

5.10

2.67

tmaxa (h)

0.50

0.25–8

0.50

0.22–1.5

0.45

0.25–1.5

0.50

0.25–0.75

t½ (h)

27.5b

9.02

17.4c

6.76

16.0d

5.04

15.1e

3.35

AUC0-t (pg.h/mL)

2.29

1.17

7.84

2.82

13.3

4.48

28.0

11.0

AUC (pg.h/mL)

5.95b

2.66

12.5c

6.01

19.7d

4.48

38.1e

14.1

CL/f (L/h)

119b

40

252c

135

268d

70.6

310e

161

Vz/f (L)

4345b

753

5736c

2629

6219d

2675

7060e

5199

  1. AUC 0-t area under the concentration-time curve from zero to the last quantifiable time point, AUC area under the concentration-time curve, CL/f total body clearance of drug from plasma after extravascular administration, C max maximum measured plasma concentration, COPD chronic obstructive pulmonary disease, h hour(s), n number of patients with data, PK pharmacokinetic, SD standard deviation, t max time to reach maximum concentration, t ½ terminal elimination half-life, V z /f apparent volume of distribution during terminal phase after extravascular administration
  2. amedian value (min-max), bn = 5, cn = 11, dn = 12, en = 9